- Home
- USAU vs XOMA Comparison
USAU vs XOMA Comparison
Compare USAU & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | XOMA |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 308.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | USAU | XOMA |
|---|---|---|
| Price | $21.59 | $25.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $22.83 | ★ $60.60 |
| AVG Volume (30 Days) | ★ 329.8K | 180.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,402,000.00 | N/A |
| Revenue This Year | N/A | $77.29 |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $18.40 |
| 52 Week High | $23.72 | $39.92 |
Technical Indicators
Market Signals| Indicator | USAU | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 53.13 |
| Support Level | $18.58 | $23.71 |
| Resistance Level | $23.58 | $27.73 |
| Average True Range (ATR) | 1.05 | 1.23 |
| MACD | 0.50 | 0.38 |
| Stochastic Oscillator | 99.47 | 78.20 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.